We are very pleased to announce our partnership in Indonesia by acquiring majority of shares & management control of PT Citra Pharma Indonesia from current shareholders. It will now operate under the new name PT Wellesta CPI Healthcare and will be based from Jakarta. PT Citra Pharma Indonesia is in successful operations for last 12-years and have been partner with MNC players in Pharma and Healthcare sector in the Indonesian market. PT Citra Pharma provides medical sales & marketing services to MNC in Indonesia with successful and compliant track record.

This company was founded by Pak Budi, Pak Chan, Pak Freddy & Pak Agus. At present PT Wellesta CPI is led by Pak Freddy Hidajat as President Director. Indonesia is one of the fastest growing pharmaceutical markets in Asia and offers us good opportunity to partner with present MNCs in the country & companies who want to enter Indonesian market.

Our goal is to provide high quality professional services and support provide high quality healthcare products at optimum price to improve health to masses. We foresee this partnership will help accomplish our Vision and Mission through PT Wellesta CPI Healthcare in Indonesia. Our focus would be driven through our dedicated efforts, strong in-market experience, determination and veracity.

Mr. Slamet Achmad has been appointed as Product Manager for PT. Wellesta CPI Indonesia, effective from 1th December 2019.

Mr. Slamet started his career at PT Dumex Indonesia as Medical Representative in 1992. In 1997, he then transited to a Medical Representative in PT Pfizer Indonesia. He was promoted to District Sales Manager in 2002 and Product Manager in 2005. In 2015, he joined PT Citra Pharma Indonesia as Product Manager.

We at Wellesta are very optimistic about Indonesian Healthcare Market & opportunities for Wellesta to progress. We are sure that Mr Slamet’s expertise will help achieve our Vision & Mission. Mr Slamet will report directly to Yohannes Sinaga, Country Manager of PT Wellesta CPI Indonesia.

We welcome Mr. Slamet to the Wellesta family and wish him great success in his new position.

We are pleased to announce the appointment of Dr. Hanadi Setiarto as Country Group Head for Wellesta Indonesia. Before joining Wellesta, Dr. Hanadi was President Director of PT ACTAVIS Indonesia, a TEVA PHARMACEUTICAL subsidiary. He is a seasoned commercial leader with 32 years of experience within the pharmaceutical industry.

Dr. Hanadi began his career in 1992 and held various managerial roles for 12 years at Dumex Alpharma Indonesia (now Actavis) and Bristol Myers Squibb Indonesia. He later joined PT Novartis Indonesia as Commercial Operations Director. He worked for 6 years, where he identified and developed long-run and mid-term strategies for the Primary Care and Vaccine business unit. In early 2010, he established Pfizer’s legal entity, Pfizer Parke Davis, in Indonesia as a part of Pfizer’s global generic initiative while working as Pharma Sales Director/GM Pfizer Generic at PT Pfizer Indonesia.

Dr. Hanadi also worked as Country Manager at Mundipharma Laboratories GmbH, where he defined, developed, and implemented Indonesia’s market entry strategy. Before his previous role as President Director at PT Actavis, Indonesia, Dr. Hanadi was the Overseas Business Director for PT Dexa Medica (Dexa Group) until September 2017. During his tenure, he was responsible for key growth strategies for the export market for DEXA MEDICA in 16 countries within ASIA and AFRICA, and strengthening company operations in each country.

Dr. Hanadi holds a Master’s degree in International Marketing from STIE Labora and a Medical Doctorate in General Medicine from Krida Wacana Christian University, Jakarta. He will report to Mr. Milan Paleja, our Chairman & MD of Wellesta Group.

With Dr Hanadi’s appointment, we have created Wellesta Indonesia in 3 Division’s:
(1) Ethical (2) Medical Devices & Diagnostics (MD & D) (3) Direct to Consumer (DTC)

Mr. Yohannes Sinaga will continue to lead our Ethical Business in Indonesia, and he will be reporting to Dr Hanadi. We are in the process of appointing leaders for MD&D and DTC for Indonesian Business.

We welcome Dr. Hanadi Setiarto to the Wellesta family and wish him great success in his new role.

Mr. Yohannes Sinaga has been appointed as the Country Manager for PT Wellesta CPI Indonesia, effective from 1st May 2020.

His last position was Chief Marketing Officer for AstraZeneca Indonesia. He has extensive experience with 15 years in pharmaceutical industry.

Mr. Sinaga has experience in various positions including sales and marketing, as well as various experiences in varied therapeutic areas. He has extensive engagement with Medical Association Groups including the association of Pediatrician, Psychiatry, Internal Medicine, Hematology – Oncology, Surgical Oncology, Pathology, Pulmonology, Hepatology, Nephrology, Virology, Neurology, Rheumatology, Urology, Gynecology, as well as with Government Stakeholders.

Mr. Sinaga’s career started as Product Specialist for Novartis in 2006, then moved to marketing role as a Product Manager, he worked with Novartis for 5 years. In 2011, he decided to move to Roche Indonesia as an Oncology Product Manager, 1 year later was promoted as a Group Product Manager and later was appointed as Business Unit Head. He joined AstraZeneca (AZ) in 2016 as a Business Unit Director for Respiratory Disease as well as to leading Core Products and later to lead the Learning & Development Department. Mr. Sinaga was a member of AstraZeneca International Marketing Excellence Champion with the role to set Respiratory strategy plan to countries in international region.

Mr. Sinaga holds MBA from IPMI International Business School in Jakarta as well as a Certified Pharmacist/Apothecary from University of Padjadjaran Bandung – Indonesia.

We at Wellesta are very optimistic about Indonesian Healthcare Market & opportunities for Wellesta to progress. We are sure that Mr. Sinaga’s leadership the Indonesia team will help achieve our Vision & Mission. Mr. Sinaga will report to Milan Paleja, Director of PT Wellesta CPI Healthcare & also Chairman & MD of Wellesta Group.

We welcome Mr. Yohannes Sinaga to Wellesta family and wish him great success in his new position.

Wellesta Holding, dengan senang hati mengumumkan penunjukkan Bpk Yohannes Sinaga (Mr Joe) sebagai Country Manager PT Wellesta CPI Indonesia, efektif per 1 Mei 2020.

Posisi terakhir Mr Joe adalah sebagai Chief Marketing Officer di AstraZeneca Indonesia. Beliau memiliki pengalaman yang luas dengan lebih dari 15 tahun bekecimpung di bidang industry farmasi. Mr. Joe mempunyai pengalaman di industri farmasi baik di sales dan marketing di berbagai bidang terapeutik, serta terlibat dengan berbagai asosiasi kedokteran, diantaranya asosiasi dokter anak, psikiatri, penyakit dalam, hematologi – onkologi, patologi, bedah, pulmonology, hepatology, nefrologi, neurologi, rematologi, ginekologi, serta stakeholder dari pemerintah.

Mr. Joe memulai karir sebagai Product Specialist di PT Novartis Indonesia, kemudian sebagai Product Manager. Setelah kurang lebih 5 tahun di PT Novartis, di tahun 2011, beliau bergabung dengan PT Roche, dimana disini, ia mendapatkan berbagai jenis posisi, mulai dari Group Product Manager, kemudian mendapat jabatan sebagai Business Unit Head baik di divisi specialty products dan juga di divisi Oncology. Di tahun 2016, beliau bergabung dengan PT AstraZeneca juga dengan role yang beragam, mulai dari Direktur Unit Bisnis Respiratory dan Core, kepala Learning dan Development serta terakhir sebagai Chief Marketing Officer. Beliau juga merupakan Champion dari International Marketing Excellence yang bertugas untuk menetapkan strategi Respiratory di Region International AstraZeneca.

Mr. Joe lulusan Farmasi Unpad serta memperoleh pendidikan MBA dari IPMI International Business School Jakarta.

Dengan market dan peluang yang besar di Indonesia, kita optimis, bahwa Wellesta akan berkembang pesat, serta dibawah kepemimpinan Mr. Joe, Wellesta CPI akan mencapai visi dan misi perusahaan.

Kami sangat senang hati mengumumkan kemitraan kami di Indonesia dengan mengakuisisi mayoritas saham & kontrol manajemen PT Citra Pharma Indonesia dari pemegang saham saat ini. Sekarang akan beroperasi dengan nama baru PT Wellesta CPI Healthcare dan akan berbasis dari Jakarta. PT Citra Pharma Indonesia telah beroperasi selama 12 tahun terakhir dan telah bermitra dengan para pemain MNC di sektor Farmasi dan Kesehatan di pasar Indonesia. PT Citra Pharma menyediakan layanan penjualan & pemasaran medis kepada MNC di Indonesia dengan rekam jejak yang sukses dan mengutamakan kepatuhan.

Perusahaan ini didirikan oleh Pak Budi, Pak Chan, Pak Freddy & Pak Agus. Saat ini PT Wellesta CPI dipimpin oleh Pak Freddy Hidajat sebagai Direktur Utama. Indonesia adalah salah satu pasar farmasi dengan pertumbuhan tercepat di Asia dan menawarkan kami kesempatan yang baik untuk bermitra dengan MNC masa kini di negara ini & perusahaan yang ingin memasuki pasar Indonesia.

Tujuan kami adalah untuk memberikan layanan dan dukungan profesional berkualitas tinggi menyediakan produk perawatan kesehatan berkualitas tinggi dengan harga optimal untuk meningkatkan kesehatan kepada masyarakat. Kami meramalkan kemitraan ini akan membantu mencapai Visi dan Misi kami melalui PT Wellesta CPI Healthcare di Indonesia. Fokus kami akan didorong melalui upaya berdedikasi kami, pengalaman, tekad, dan kebenaran di pasar yang kuat.

Slamet Achmad telah ditunjuk sebagai Product Manager untuk untuk PT. Wellesta CPI Indonesia berlaku mulai 1 Desember 2019.

Slamet memulai karirnya di PT Dumex Indonesia sebagai Medical Representative pada tahun 1992 dan bergabung di PT Pfizer Indonesia sebagai Medical Representative pada tahun 1997. Dia mendapatkan promosi menjadi District Sales Manager di tahun 2002 dan Product Manager di tahun 2005. Slamet mulai bergabung di PT Citra Pharma Indonesia sebagai Product Manager sejak tahun 2015.

Kami di Wellesta sangat optimis dengan Pasar Kesehatan Indonesia & peluang bagi Wellesta untuk maju. Kami yakin bahwa dengan keahlian Slamet akan membantu mencapai Visi & Misi kami. Slamet akan melapor kepada Marketing Head PT Wellesta CPI.

Kami menyambut Slamet untuk keluarga Wellesta dan berharap kesuksesan besarnya dalam posisi barunya